Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Top Research Reports For May 4, 2017

Published 05/04/2017, 05:41 AM
Updated 07/09/2023, 06:31 AM

Thursday May 4, 2017

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), JPMorgan (NYSE:JPM) (JPM) and Union Pacific (UNP).

Exxon Mobil shares tracked the S&P 500 index through year-end 2016, but have lagged the broader index as well as the peer super majors group in the year-to-date period, likely reflecting the company's perceived defensiveness that disadvantages it relative to its 'oilier' peers. During first-quarter 2017, the company posted strong earnings on the back of increased realizations for liquids and gas as well as higher margin from the downstream business.

Exxon's resilient integrated business model has long been the industry gold standard, which makes it an attractive and relatively low-risk Energy sector option for many investors. A fortress balance sheet, an attractive and totally safe dividend and a history of returning excess cash to shareholders are some of the other positives in the Exxon story.

The Zacks analyst discusses the pros and cons of investing in Exxon shares in the updated research report issued today. (You can read the full research report on Exxon Mobil here.)

Shares of JPMorgan have gained +24.5% over the past six months vs. +23.9% gain for the Major Banks industry. The company’s first-quarter 2017 earnings easily outpaced expectations driven by impressive investment banking and trading revenue growth as well as lower credit costs.

The Zacks analyst likes the company’s has steady capital deployment activities (dividend hike and share buyback), which reflects its strong balance sheet position. The company remains well positioned to benefit from the improved rate scenario and rising loan demand. Synergies from retail banking performance and cost-containment efforts will help improving its profitability, going forward.

However, a persistent fee income growth challenge remains a major headwind. Also, litigation hassles remain a concern. (You can read the full research report on JPMorgan here.)

Union Pacific shares have rallied 3.8% in the last month, outperforming the Zacks Transportation-Rail industry’s increase of 3.66% in the period. Shares of Union Pacific have also performed better than those of fellow-railroad operator Norfolk Southern (NYSE:NSC), which have gained 2.2% in the same time span.

Union Pacific reported better-than-expected earnings and revenues in the first quarter of 2017. The improvement in coal revenues and the company's 2017 capital plan worth $3.1 billion are other positives. The plan complements the company's efforts to promote safety and enhance productivity. The below-par performance of the automotive unit in the first quarter, however, raises concerns. (You can read the full research report on Union Pacific here.)

Other noteworthy reports we are featuring today include Biogen (NASDAQ:BIIB) (BIIB), ADP (ADP) and Becton Dickinson (BDX).

More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple (NASDAQ:AAPL)'s 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.

A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>

Mark Vickery

Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>

Featured Reports

Biogen (BIIB) Q1 Results Top, Spinraza Sales Strong

The Zacks analyst is encouraged by the stronger-than-expected sales of newly launched drug Spinraza for spinal muscular atrophy

ADP (ADP) Beats Q3 Earnings Estimates, New Bookings Decline

The Zacks analyst thinks ADP holds a dominant position in the payroll processing and human capital management market, primarily due to its robust product portfolio.

Entergy (NYSE:ETR) Misses on Q1 Earnings, Revenues Down Y/Y

The Zacks analyst thinks Entergy's first-quarter 2017 earnings lagged the Zacks Consensus Estimate and also declined year over year due to mild weather. However, revenues surpassed the consensus mark.

Becton, Dickinson (BDX) Tops Q2 Earnings, Forex Woes Hurt

The covering analyst is bullish on Bacton Dickinson's stellar Q2 results, driven by year-over-year growth in BD Life sciences segment. Significant exposure to foreign exchange volatility is a concern.

Hess (HES) Posts Narrower-Than-Expected Loss in Q1

The Zacks analyst agrees that higher oil price realizations led Hess to post narrower than expected loss in Q1.

Sprint (S) Incurs Wider-than-Expected Q4 Loss, Revenues Top

The covering analyst thinks Sprint's wireless expansion plans and network modernization efforts might have driven 59.702 million wireless customers in the 4Q16.

Fidelity (FIS) Q1 Results Reflect Improving Revenue Trends

The covering analyst thinks Fidelity's Q1 results reflect organic growth with increasing revenues. Moreover, strategic acquisitions bolster its growth prospects.

New Upgrades

Garmin (GRMN) Beats Q1 Earnings and Revenues

The Q1 earnings beat apart, the Zacks analyst is positive on Garmin's continued innovation, diversification and market expansion efforts for growth in all business segments.

Clean Harbors (CLH) Q1 Sales Up on Solid Demand, View Intact

Clean Harbors reported relatively modest first-quarter 2017 results with healthy improvement in revenues owing to operating leverage in the business model and gradual uptick in customer activity.

CNA Financial (CNA) Beats Q1 Earnings Estimates

CNA Financial's first-quarter 2017 earnings beat expectations and improved year over year on higher investment income and solid performance at International and Life and Group Non-Core segments.

New Downgrades

Duke Realty (DRE) Beats on Q1 FFO, to Sell Healthcare Assets

The covering analyst thinks Duke Realty will witness earnings-dilutive effects, with its recent decision to sell healthcare portfolio. However, the company recorded better-than-expected Q1 results.

Insperity (NSP) Misses Q1 Earnings & Revenue Estimates

Insperity continues to face troubles due to weakness in client hiring. But the booming PEO industry should boost the company's prospects going ahead, per the Zacks analyst.

athenahealth (ATHN) Q1 Earnings & Revenues Lag Estimates

athenahealth missed earnings and revenue estimates in first-quarter 2017. Also, intensifying market competition coupled with lower bookings are likely to mar growth prospects in the near term.



Exxon Mobil Corporation (NYSE:XOM): Free Stock Analysis Report

Union Pacific Corporation (NYSE:UNP): Free Stock Analysis Report

J P Morgan Chase & Co (JPM): Free Stock Analysis Report

Biogen Inc. (BIIB): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

Automatic Data Processing, Inc. (ADP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.